Characteristics and Outcome of Patients with Core Binding
Factor Acute Myeloid Leukemia and FLT3-ITD: Results from an
International Collaboration

a 2019

Characteristics and Outcome of Patients with Core Binding Factor Acute Myeloid Leukemia and FLT3-ITD: Results from an International Collaboration

KAYSER, S.; M. A. ELLIOTT; M. LUSKIN; A. M. BRUNNER; M. KRAMER et al.

Základní údaje

Originální název

Characteristics and Outcome of Patients with Core Binding Factor Acute Myeloid Leukemia and FLT3-ITD: Results from an International Collaboration

Autoři

Vydání

2019

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 17.794

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/19:00117540

Organizační jednotka

Lékařská fakulta

ISSN

DOI

https://doi.org/10.1182/blood-2019-125317

UT WoS

000577160406074

Klíčová slova anglicky

Core Binding Factor Acute Myeloid Leukemia; FLT3-ITD

Štítky

rivok

Příznaky

Mezinárodní význam

Změněno: 4. 1. 2021 14:38, Mgr. Tereza Miškechová

Anotace

V originále

Core binding factor acute myeloid leukemia (CBF-AML) is defined by the presence of either t(8;21)(q22;q22) or inv(16)(p13.1q22)/t(16;16)(p13.1;q22) and is associated with a favorable outcome, particularly if treated with repetitive cycles of high-dose cytarabine as post-remission therapy. Long-time 10-year overall survival (OS) rate was reported of 58% in FLT3-ITD negative patients (pts; Allen et al. Leukemia 2013). Nevertheless, 30-40% CBF-AML pts experience relapse. FLT3-ITD mutations occur in roughly 5-10% of adult CBF-AML. However, their prognostic relevance is still controversial.

Citovat

KAYSER, S.; M. A. ELLIOTT; M. LUSKIN; A. M. BRUNNER; M. KRAMER; Zdeněk RÁČIL; Zuzana NOVÁKOVÁ; P. CETKOVSKY; J. NOVAK; F. STOELZEL; C. THIEDE; C. MULLER-TIDOW; U. PLATZBECKER; C. ROLLIG; R. F. SCHLENK a M. J. LEVIS. Characteristics and Outcome of Patients with Core Binding Factor Acute Myeloid Leukemia and FLT3-ITD: Results from an International Collaboration. 2019. ISSN 0006-4971. Dostupné z: https://doi.org/10.1182/blood-2019-125317.

@proceedings{1718078,
   author = {Kayser, S. and Elliott, M. A. and Luskin, M. and Brunner, A. M. and Kramer, M. and Ráčil, Zdeněk and Nováková, Zuzana and Cetkovsky, P. and Novak, J. and Stoelzel, F. and Thiede, C. and MullerandTidow, C. and Platzbecker, U. and Rollig, C. and Schlenk, R. F. and Levis, M. J.},
   doi = {https://doi.org/10.1182/blood-2019-125317},
   keywords = {Core Binding Factor Acute Myeloid Leukemia; FLT3-ITD},
   language = {eng},
   title = {Characteristics and Outcome of Patients with Core Binding Factor Acute Myeloid Leukemia and FLT3-ITD: Results from an International Collaboration},
   url = {https://ashpublications.org/blood/article/134/Supplement_1/2693/423109/Characteristics-and-Outcome-of-Patients-with-Core},
   year = {2019}
}

TY  - CONF
ID  - 1718078
AU  - Kayser, S. - Elliott, M. A. - Luskin, M. - Brunner, A. M. - Kramer, M. - Ráčil, Zdeněk - Nováková, Zuzana - Cetkovsky, P. - Novak, J. - Stoelzel, F. - Thiede, C. - Muller-Tidow, C. - Platzbecker, U. - Rollig, C. - Schlenk, R. F. - Levis, M. J.
PY  - 2019
TI  - Characteristics and Outcome of Patients with Core Binding Factor Acute Myeloid Leukemia and FLT3-ITD: Results from an International Collaboration
KW  - Core Binding Factor Acute Myeloid Leukemia
KW  - FLT3-ITD
UR  - https://ashpublications.org/blood/article/134/Supplement_1/2693/423109/Characteristics-and-Outcome-of-Patients-with-Core
L2  - https://ashpublications.org/blood/article/134/Supplement_1/2693/423109/Characteristics-and-Outcome-of-Patients-with-Core
N2  - Core binding factor acute myeloid leukemia (CBF-AML) is defined by the presence of either t(8;21)(q22;q22) or inv(16)(p13.1q22)/t(16;16)(p13.1;q22) and is associated with a favorable outcome, particularly if treated with repetitive cycles of high-dose cytarabine as post-remission therapy. Long-time 10-year overall survival (OS) rate was reported of 58% in FLT3-ITD negative patients (pts; Allen et al. Leukemia 2013). Nevertheless, 30-40% CBF-AML pts experience relapse. FLT3-ITD mutations occur in roughly 5-10% of adult CBF-AML. However, their prognostic relevance is still controversial.
ER  -

KAYSER, S.; M. A. ELLIOTT; M. LUSKIN; A. M. BRUNNER; M. KRAMER; Zdeněk RÁČIL; Zuzana NOVÁKOVÁ; P. CETKOVSKY; J. NOVAK; F. STOELZEL; C. THIEDE; C. MULLER-TIDOW; U. PLATZBECKER; C. ROLLIG; R. F. SCHLENK a M. J. LEVIS. \textit{Characteristics and Outcome of Patients with Core Binding Factor Acute Myeloid Leukemia and FLT3-ITD: Results from an International Collaboration}. 2019. ISSN~0006-4971. Dostupné z: https://doi.org/10.1182/blood-2019-125317.

Přehled o publikaci